First Tracks Biotherapeutics Inc (TRAX) FinancialsTRAXFirst Tracks Biotherapeutics Inc

In the context of the broader market, TRAX competes directly with industry leaders such as KARD and TYRA. With a market capitalization of $1.55B, it holds a leading position in the sector. When comparing efficiency, TRAX's gross margin of N/A stands against KARD's N/A and TYRA's N/A. Such benchmarking helps identify whether First Tracks Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has experienced significant losses, with a net income of -33,374,000 USD in Q2 2026 and an EPS of -0.95. However, the current ratio has improved to 14.28, indicating better liquidity.